Literature DB >> 23775956

Ipilimumab administration in patients with advanced melanoma and hepatitis B and C.

Anupa Sharma1, John A Thompson, Aparna Repaka, Janice M Mehnert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23775956     DOI： 10.1200/JCO.2012.47.1946

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  Predictors of immunotherapy-induced immune-related adverse events.

Authors:  A Kartolo; J Sattar; V Sahai; T Baetz; J M Lakoff
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

2.  Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection.

Authors:  Tasuku Nakabori; Yutaro Abe; Sena Higashi; Takeru Hirao; Yasuharu Kawamoto; Shingo Maeda; Kazuma Daiku; Makiko Urabe; Yugo Kai; Ryoji Takada; Takuo Yamai; Kenji Ikezawa; Hiroyuki Uehara; Kazuyoshi Ohkawa
Journal:  JGH Open       Date:  2022-04-22

Review 3.  Hepatitis C virus reactivation in cancer patients in the era of targeted therapies.

Authors:  Ozan Yazici; Mehmet Ali Nahit Sendur; Sercan Aksoy
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

4.  Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series.

Authors:  Sowmya Ravi; Kristen Spencer; Mary Ruisi; Nageatte Ibrahim; Jason J Luke; John A Thompson; Keisuke Shirai; David Lawson; Heddy Bartell; Ragini Kudchadkar; Ngoc Thi Gunter; Janice M Mehnert; Evan J Lipson
Journal:  J Immunother Cancer       Date:  2014-10-14       Impact factor: 13.751

Review 5.  Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer.

Authors:  Isobel S Okoye; Michael Houghton; Lorne Tyrrell; Khaled Barakat; Shokrollah Elahi
Journal:  Front Immunol       Date:  2017-09-29       Impact factor: 7.561

6.  Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review.

Authors:  Dan Pu; Liyuan Yin; Yuwen Zhou; Wen Li; Lin Huang; Liang Cai; Qinghua Zhou
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

7.  Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors.

Authors:  Jianing Chen; Yaokai Wen; Xiangling Chu; Yuzhi Liu; Chunxia Su
Journal:  Front Pharmacol       Date:  2022-08-30       Impact factor: 5.988

Review 8.  Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations.

Authors:  Michael J Grant; Nicholas DeVito; April K S Salama
Journal:  Melanoma Manag       Date:  2018-10-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.